Steroid-Withdrawal at 3 Days after Renal Transplantation with Anti-IL-2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study

American Journal of Transplantation

Volumn 4, Issue 5, 2004, Pages 803-810

  Ter Meulen, Cornelis G ^a   Van Riemsdijk, Iza ^b   Hené, Ronald J ^c   Christiaans, Maarten H L ^d   Borm, George F ^a   Van Gelder, Teun ^b   Hilbrands, Luuk B ^a   Weimar, Willem ^b   Hoitsma, Andries J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Interleukin 2 receptor; Kidney transplantation; Monoclonal antibodies; Post transplant diabetes; Rejection

Indexed keywords

CALCIUM; COTRIMOXAZOLE; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN; STEROIDS; TACROLIMUS; TIME FACTORS;

EID: 2442547816     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00419.x     Document Type: Article

References (36)

1. Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839.
2. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359.
3. Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991;51:374-377.
4. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874.
5. Smak Gregoor PJ, De Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373.
6. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
7. Hollander AA, Hene RJ, Hermans J, van Es LA, van der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8: 294-301.
8. Ponticelli C, Tarantino A, Segoloni GP et al. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation. Italian Multicentre Study Group for Renal Transplantation (SIMTRe). J Am Soc Nephrol 1997; 8: 638-646.
9. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999; 318: 1104-1107.
10. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746.
11. Squifflet JP, Vanrenterghem Y, Van Hooff JP, Salmela K, Rigotti P. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34: 1584-1586.
12. Shapiro R, Jordan ML, Scantlebury VP et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999; 67: 411-415.
13. Boots JM, Christiaans MH, Van Duijnhoven EM, Van Suylen RJ, Van Hooff JP. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-1709.
14. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110-115.
15. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165.
16. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
17. Sarwal MM, Yorgin PD, Alexander S et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13-21.
18. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72: 845-850.
19. Vincenti F, Lantz M, Birnbaum J et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33-38.
20. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988; 16: 128-140.
23. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-20.
24. Alarcon-Zurita A, Munar MA, Losada P et al. Steroids withdrawal after 3 months of successful renal transplantation using a tacrolimus-and mycophenolate-based immunosuppression. Transplant Proc 2002; 34: 118-119.
25. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841.
26. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643-648.
27. Hilbrands LB, Hoitsma AJ, Koene RA. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation. Transplantation 1996; 61: 1038-1046.
28. van Acker BA, Prummel MF, Weber JA, Wiersinga WM, Arisz L. Effect of prednisone on renal function in man. Nephron 1993; 65: 254-259.
29. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003; 75: 1260-1266.
30. ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001; 72: 1709-1710.
31. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568-573.
32. Eckhoff DE, McGuire B, Sellers M et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867-1872.
33. Baran DA, Ashkar J, Galin ID et al. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. Transplant Proc 2002; 34: 1711-1712.
34. Shapiro R, Jordan ML, Scantlebury VP et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995; 59: 485-490.
35. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868-871.
36. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72: S5-S8.